Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?
NCT ID NCT06316531
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This phase 3 trial is comparing an experimental drug, BL-M07D1, against the approved therapy T-DM1 in people with advanced HER2-positive breast cancer that has not responded to previous treatments. The study aims to see whether BL-M07D1 can delay cancer progression better than T-DM1. Participants will receive either drug by infusion every three weeks, and researchers will track how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental antibody-drug conjugate called BL-M07D1
- What this could lead to
- If BL-M07D1 proves more effective than T-DM1, it could offer a new treatment option for people with advanced HER2-positive breast cancer who have already tried standard therapies.
- What could go wrong
- This is an early-phase 3 trial, so results are not yet known. BL-M07D1 may not be more effective than T-DM1 and could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outsmart resistant breast cancer?
- Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer
- Could a simple blood test let some breast cancer patients stop treatment?
- New drug cocktail aims to outsmart resistant breast cancer
- Blood test may predict breast cancer treatment success
- Immunotherapy combo aims to wipe out HER2 breast cancer before surgery